Janssen Business Development

Identifying Pathways to Better Health
Through Collaboration

Learn more

About Us

Johnson & Johnson Innovation | Janssen Business Development seeks to identify collaborative opportunities that will create transformative value for our partners and the world.

Driving Collaborative Innovation to Accelerate Breakthroughs

If you are with an established pharmaceutical company, mid-sized to large biotechnology company, seek a collaboration or merger & acquisition discussions, or have a compound that has shown proof of concept in humans, make the connection with Johnson & Johnson Innovation, Janssen Business Development.

Janssen Business Development is very active in acquiring assets, companies, and technologies as well as entering into strategic collaborations, including joint ventures, developments, and commercial partnerships.

Team

  • Patrick Verheyen
    Global Head, Janssen Business Development
  • Marianne De Backer
    Marianne De Backer
    VP, Global M&A Operations and Divestitures (Pharmaceuticals Group), Global Infectious Diseases & Vaccines Business Development
  • Nicholas Franco
    Actelion Executive Vice President, Chief Business Development Officer
  • Johan L. J. Verbeeck
    VP, Business Development, Immunology
  • Lucinda Warren
    VP, Business Development, Neuroscience
  • Debi Watson
    VP, Business Development, Oncology

Approach

The Janssen Business Development team focuses on mid- and late-stage collaborations with established pharmaceutical and larger biotechnology companies to accelerate breakthrough innovation to solve unmet medical needs and create real value in Janssen’s six defined therapeutic areas.

Strong Science Is at the Heart of Everything We Do

Our approach meaningfully integrates deal makers with science leaders from the very beginning. Having a clear and focused strategy that is grounded in the science allows the Janssen Business Development team to shape better deals and achieve in-market impact faster by understanding where each partner can add value.

Proven Two-Way Value Can Be Found in Every Partnership

The Janssen Business Development team has a proven, positive track record of deal performance. Our thoughtful approach to risk-taking includes spending the time to understand the needs of our partners so that deals can be structured to maximize value for all parties.

Dynamic Approaches Pave the Way to Success

Since no two deals are exactly alike, the Janssen Business Development team employs a flexible and adaptive approach to tailor the optimal deal structure to each unique partner opportunity. Our direct access to decision makers within Johnson & Johnson allows for creative and timely problem solving to optimize success.

True Collaboration Drives All of Our Actions

We are focused on genuine collaborations and seek out relationships with partners who desire transparency and openness, which we believe leads to new ideas and better solutions. Our goal is to form active partnerships where we can bring the full strength of Johnson & Johnson to bear to create a lasting and valuable relationship.

Focus Areas

Our Pharmaceuticals business is divided into six core areas, Cardiovascular & Metabolism; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Janssen Business Development seeks innovation across all of these areas where there is significant unmet patient need. 

  • Type 2 Diabetes
    Cardiovascular and Metabolism
    Cardiovascular and Metabolism
  • Psoriasis, Inflammatory Bowel Disease, Rheumatoid Arthritis
    Immunology
    Immunology
  • Respiratory Infections, Hepatitis
    Infectious
    Diseases and Vaccines
    Infectious Diseases and Vaccines
  • Mood Disorders, Alzheimer's Disease
    Neuroscience
    Neuroscience
  • Prostate Cancer, Lung Cancer, Hematologic Malignancies
    Oncology
    Oncology
  • Pulmonary arterial hypertension, Idiopathic pulmonary fibrosis, Chronic thromboembolic pulmonary hypertension
    Pulmonary Hypertension
    Pulmonary Hypertension

News

  • Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimen

    Horsham, PA
    May 2, 2018

    Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a definitive agreement under which it will acquire BeneVir Biopharm, Inc. (BeneVir), a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies. BeneVir utilizes a proprietary T-Stealth™ Oncolytic Virus Platform to engineer oncolytic viruses, tailored to infect and destroy cancer cells.  Johnson & Johnson Innovation LLC facilitated the transaction.

  • Johnson & Johnson Innovation Champions Leading Edge Science with 15 New Collaborations with Potential to Impact Patients’ Lives

    New Brunswick, NJ
    January 5, 2018

    Johnson & Johnson Innovation LLC today announced more than a dozen new collaborations to drive the development of novel solutions to impact healthcare. These collaborations bring the total number of strategic transactions executed by Johnson & Johnson Innovation to more than 350 since its establishment in 2012.

    This latest series of deals focuses on leveraging advances in science and technology to address areas of high unmet medical need, including the use of artificial intelligence to detect signs of Alzheimer’s disease years before it becomes apparent; the identification of throat cancers with a simple saliva test; and harnessing the microbiome to treat sleep disorders.

  • Johnson & Johnson Announces Completion of Acquisition of Actelion

    New Brunswick, NJ
    June 16, 2017

    Transaction Expands Janssen Portfolio with Leading Differentiated In-Market Medicines and Promising Late-Stage Therapies.

Pages

Contact us

Make the Connection

We look forward to our first discussion. If you would like to discuss a collaboration,
simply click the contact us button which will connect you to our Idea Portal and a member of our team will contact you.

Johan Verbeeck, DVM, MsC
Johnson & Johnson Innovation,
Janssen Business Development
Email: jverbee2@ITS.JNJ.com
Telephone: +1 609-730-4532

contact

Accelerators

Close
Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
mail@www.neomed.ca
www.neomed.ca
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.